Ultragenyx Pharmaceutical Inc. Share Price & Technical Analysis
RARE · $23.39 (-1.35%)
Healthcare / Biotechnology
$23.39
-1.35%
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth fact…
Price chart
Seasonality
May has 1 positive and 4 negative years (last 5 years shown)
-6% return in May, -2% avg return in past 3 year May month.
10% return in 2026, -13% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 6% | -1% | -7% | 18% | -6% | – | – | – | – | – | – | – | 10% |
| 25 | 2% | 2% | -15% | 8% | -13% | 6% | -25% | 11% | -1% | 15% | 2% | -33% | -41% |
| 24 | -7% | 16% | -11% | -9% | -6% | 1% | 10% | 26% | -1% | -8% | -7% | -12% | -7% |
| 23 | -2% | -2% | -10% | 9% | 14% | -6% | -6% | -14% | -4% | -1% | 10% | 23% | 10% |
| 22 | -17% | -4% | 8% | -3% | -33% | 26% | -11% | -8% | -13% | -4% | -11% | 27% | -43% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Neutral
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome. It also develops UX701 that is in Phase 2 clinical trial for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; GeneTx; Mereo; University of Pennsylvania; Solid Biosciences Inc.; Regeneron; Abeona; and Arcturus Therapeutics Holdings Inc. The company was incorporated in 2010 and is headquartered in Novato, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$2.60B
P/E ratio
—
52W high
$42.37
52W low
$18.29
Volume
11,30,550
Beta
0.39
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Ultragenyx Pharmaceutical Inc. share price today?
- Ultragenyx Pharmaceutical Inc. (RARE) last traded around $23.39 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does RARE have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for RARE. Download the app for real-time alerts.
- How can I analyze Ultragenyx Pharmaceutical Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.